Apollo Endosurgery Inc. Daily Stock Analysis

Daily Stock Analysis, APEN, Apollo Endosurgery Inc, priceseries

Apollo Endosurgery Inc. Daily Stock Analysis
Stock Information
Open
6.78
Close
6.53
High
6.78
Low
6.51
Previous Close
6.75
Daily Price Gain
-0.22
YTD High
9.11
YTD High Date
Jan 3, 2022
YTD Low
4.52
YTD Low Date
Feb 23, 2022
YTD Price Change
-2.24
YTD Gain
-25.54%
52 Week High
10.39
52 Week High Date
Nov 16, 2021
52 Week Low
4.52
52 Week Low Date
Feb 23, 2022
52 Week Price Change
0.77
52 Week Gain
13.37%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 11. 2017
6.86
May 12. 2017
7.76
1 Trading Days
13.05%
Link
LONG
Jul 24. 2017
6.75
Jul 27. 2017
7.11
3 Trading Days
5.33%
Link
LONG
Sep 29. 2017
4.68
Oct 13. 2017
5.23
10 Trading Days
11.69%
Link
LONG
Dec 19. 2017
4.25
Jan 17. 2018
5.95
18 Trading Days
40.05%
Link
LONG
May 21. 2020
2.23
May 26. 2020
2.34
2 Trading Days
5.16%
Link
LONG
Nov 4. 2020
1.80
Dec 9. 2020
3.68
24 Trading Days
104.57%
Link
LONG
Feb 4. 2021
4.86
Feb 5. 2021
5.25
1 Trading Days
8.02%
Link
LONG
Mar 1. 2021
6.10
Mar 3. 2021
6.54
2 Trading Days
7.30%
Link
LONG
May 3. 2021
5.81
May 26. 2021
6.73
17 Trading Days
15.79%
Link
LONG
Jun 9. 2021
7.63
Jun 24. 2021
8.55
11 Trading Days
12.05%
Link
LONG
Aug 26. 2021
8.27
Sep 15. 2021
9.47
13 Trading Days
14.49%
Link
Company Information
Stock Symbol
APEN
Exchange
NasdaqGM
Company URL
http://www.apolloendo.com
Company Phone
512-279-5100
CEO
Todd Newton
Headquarters
Texas
Business Address
1120 SOUTH CAPITAL OF, TX HWY, BUILDING 1 SUITE 300, AUSTIN, TX 78746
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001251769
About

Apollo Endosurgery, Inc. develops medical devices. It offers medical devices for bariatric and gastrointestinal procedures. The firm's brands include Orbera, Lap-band SYSTEM and OverStitch. The company was founded by Christopher J. Gostout in 2006 and is headquartered in Austin, TX.

Description

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. It develops Lpathomab, a humanized monoclonal antibody (mAb) against lysophosphatidic acid that has completed Phase 1a clinical trial for various chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain, and pain associated with lumbosacral radiculopathy. The company also develops iSONEP, a mAb against sphingosine-1-phosphate, which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid sphingosine-1-phosphate (S1P), which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lung cancer, pancreatic cancer, and melanoma. Lpath, Inc. has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading